Skip to content
ClinCalc Pro
Menu
Plasma-derived complement inhibitor Pregnancy: §4.6: there are limited data that indicate no increased risk from the use of Berinert in pregnant women. Berinert is a physiological component of human plasma, so no studies on reproduction and developmental toxicity have been performed in animals and no adverse effects on fertility or pre- and postnatal development are expected in humans; it should be given to a pregnant woman only if clearly needed. Breast-feeding: it is unknown whether Berinert is excreted in human milk, but transfer seems unlikely given its high molecular weight; a decision must be made whether to discontinue breast-feeding or the therapy, taking into account the benefit of each. Fertility: no adverse effects expected, for the same reason.

C1-esterase inhibitor

Brand names: Berinert, Cinryze

C1-esterase inhibitor is a plasma-derived (or recombinant) replacement protein used in hereditary angioedema, both to treat acute attacks and, in some preparations, for routine prophylaxis.

Adult dose

Dose: Hereditary angioedema (HAE) type I and II — treatment of an acute angioedema attack: 20 IU/kg body weight. Pre-procedure prevention of angioedema attacks: 1000 IU, less than 6 hours before a medical, dental or surgical procedure. These are the BERINERT figures; this page also names Cinryze, whose regimen differs and is NOT sourced here.
Route: Intravenous — reconstitute per SPC §6.6 (the reconstituted solution should be colourless and clear to slightly opalescent) and administer by slow i.v. injection
Frequency: Acute attacks: per attack, as clinically required — the fetched §4.2 states no repeat-dose interval, no maximum number of doses and no routine-prophylaxis or maintenance schedule. Pre-procedure prevention: a single dose less than 6 hours before the procedure.
SCOPE — BERINERT ONLY. §4.1 verbatim: 'Hereditary angioedema type I and II (HAE) Treatment and pre-procedure prevention of acute episodes.' That is exactly this page's indication, route and population, so the dose above is published. §4.2 verbatim (Adults): 'Treatment of acute angioedema attacks: 20 IU per kilogram body weight (20 IU/kg b.w.) Pre-procedure prevention of angioedema attacks: 1000 IU less than 6 hours prior to a medical, dental, or surgical procedure.' || THE PAGE NAMES TWO BRANDS AND ONLY ONE WAS SOURCED. Brand names on this record are Berinert AND Cinryze; only Berinert 1500 IU (eMC product 7043) was fetched. The two concentrates dose differently — Berinert doses an acute attack by weight (20 IU/kg), whereas Cinryze's regimen is not in this bundle at all. Do not apply the figures above to Cinryze without its own SPC. || NO MAXIMUM IS PUBLISHED BECAUSE THE LABEL PRINTS NONE: §4.2 states no ceiling, no maximum daily total and no maximum number of doses for the 20 IU/kg attack dose, so maxDose is deliberately left empty rather than derived. §4.8 does record thrombosis — in single cases fatal — in treatment attempts with HIGH doses of Berinert for prophylaxis or therapy of Capillary Leak Syndrome, which §4.4 states is an unlicensed indication and dose and is not advised. || §4.2 also requires that treatment be initiated under the supervision of a physician experienced in the treatment of C1-esterase inhibitor deficiency.

Paediatric dose

Dose: Treatment of an acute angioedema attack: 20 IU/kg body weight — the same figure as the adult dose. Pre-procedure prevention: 15-30 IU/kg body weight, less than 6 hours before a medical, dental or surgical procedure.
Route: Intravenous (slow i.v. injection after reconstitution per §6.6)
Frequency: Per attack, as clinically required / a single dose less than 6 hours before a procedure
§4.2 Paediatric population, verbatim: 'Treatment of acute angioedema attacks: 20 IU per kilogram body weight (20 IU/kg b.w.). Pre-procedure prevention of angioedema attacks: 15 to 30 IU per kilogram body weight (15-30 IU/kg b.w.) less than 6 hours prior to a medical, dental, or surgical procedure. Dose should be selected taking into account clinical circumstances (e.g. type of procedure and disease severity).' || DELIBERATELY NOT WIRED TO THE WEIGHT CALCULATOR. dosePerKg is left null on purpose: the label prints no ceiling for 20 IU/kg, so a mounted calculator would render an uncapped 20 IU/kg x weight on a page that also names Cinryze, whose paediatric regimen is different and unsourced, with no brand selector to distinguish them. The label's own paediatric figures are stated above as text instead — they are Berinert's, are not scaled, and must not be applied to Cinryze. || The pre-procedure paediatric dose is a 15-30 IU/kg BAND that the label says must be selected on clinical circumstances; it is not a fixed figure and is not calculable.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1

Side effects

  • §4.8 states that undesired reactions with Berinert are rare; the frequency table did not survive extraction with its columns aligned, so no frequency category is assigned to the items below
  • Allergic or anaphylactic-type reactions — e.g. tachycardia, hyper- or hypotension, flushing, hives, dyspnoea, headache, dizziness, nausea
  • Shock
  • Rise in temperature
  • Reactions at the injection site
  • Development of thrombosis — reported in treatment attempts with high doses for prophylaxis or therapy of Capillary Leak Syndrome (an unlicensed indication and dose), in single cases with fatal outcome
  • Theoretical transmission of infective agents — the product is prepared from human plasma (§4.4)

Monitoring

  • Initiate treatment under the supervision of a physician experienced in the treatment of C1-esterase inhibitor deficiency
  • Give antihistamines and corticosteroids prophylactically in patients with a known tendency towards allergies
  • Stop administration immediately if allergic or anaphylactic-type reactions occur and treat according to current medical standards for shock
  • Monitor patients with laryngeal oedema particularly carefully, with emergency treatment on stand-by
  • Record the product name and batch number at every administration, to maintain the link between patient and batch
  • Consider hepatitis A and B vaccination for patients in regular or repeated receipt of human plasma-derived products
  • For home treatment or self-administration, the treating physician must ensure appropriate training is provided and review its use at intervals — data in this setting are limited
  • Do not use for unlicensed treatment of Capillary Leak Syndrome (§4.4 advises against it)

Clinical monograph

How it works

It replaces the deficient or dysfunctional C1-esterase inhibitor, restoring regulation of the complement and contact (kallikrein-kinin) systems and thereby reducing the bradykinin generation responsible for angioedema attacks.

Prescribing in practice

  • As a blood-derived product it carries a theoretical risk of transmitting infective agents and may provoke hypersensitivity reactions, so observe the patient and have facilities to manage anaphylaxis available during administration.
  • It is given by intravenous injection or infusion, with some preparations licensed for acute treatment and others for routine prophylaxis of hereditary angioedema attacks.
  • Thromboembolic events have been reported, particularly with higher exposure and in patients with risk factors for thrombosis, so weigh the benefit against this risk.

Monitoring

Monitor clinically for hypersensitivity and infusion reactions during and after administration and for signs of thromboembolism in at-risk patients.

Counselling the patient

  • Report any rash, swelling, breathlessness or other reaction during or after the infusion.
  • Patients trained for self-administration should follow the technique and storage instructions provided.
  • Carry information about your hereditary angioedema and treatment in case of emergency.

Evidence & guidelines

Use is supported by controlled trials in hereditary angioedema and by long-standing clinical guidance for managing this condition.

Reference: UK PIN HAE guidance; WAO HAE guideline; SmPC; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.